SubQ against jev on biotech diligence memos: finding the sentences a column is about
A biotech investor keeps a grid of companies and their drugs, and wants to add a column by typing its name: mechanism of action, primary endpoint, partner. Each cell should fill itself from that company's diligence memo, a long report hedwigai writes and keeps current. The first step is finding the sentences of the memo that answer the column.
We asked two decision models to do it, sentence by sentence: SubQ, from Subquadratic, and jev, from TypeSafe. Each read every sentence of 10 memos and said how likely it was to state the column for the company's own drugs. We scored both against sentences a person had marked before either model ran.
Both found far more than picking whole sections of the memo does. On mechanism of action, at the same length, SubQ found 57% of the marked sentences and jev 51%, against 41% for the sections. Across the five columns SubQ was ahead on 1, jev on 2, and 2 tied. The run cost about the same on each: $0.08 on SubQ and $0.10 on jev.
What SubQ and jev are
Both are decision models. Neither writes text. Each is given something to read and a question with fixed answers (here: does this passage state the mechanism of action of one of the company's own drugs, yes or no) and answers with a probability for each, a number from 0 to 1 for how likely it thinks that answer is right.
jev is TypeSafe's, and it already makes the small decisions inside hedwigai's research tools. SubQ's Decisions API takes the same kind of request, so the same 8,357 questions went to both, word for word.
Why judge one sentence at a time? Because the answer to a column is rarely in one place. A drug's mechanism shows up in the overview, the pipeline table and the paragraph on each product. A tool that picks the best whole section of the memo, as hedwigai's section search does, gets one or two of those places and misses the rest.
The memos and the marked sentences
Ten diligence memos on biotech companies, written by hedwigai research runs. A memo runs to 228 sentences on average (148 to 322), counting each table row and list item as one: finances, recent events, the drug pipeline, the science, the market, competitors and patents.
For each of five columns, a person marked the sentences that state it for the company's own drugs, before either model saw a memo. None of the memos has a heading for mechanism of action, so no section title gives it away.
| Column | Memos | Sentences marked |
|---|---|---|
| Mechanism of action | 10 | 87 |
| Route of administration | 6 | 21 |
| Primary endpoint | 6 | 16 |
| Partner or licensing deal | 6 | 18 |
| Patent expiry | 6 | 21 |
Results at the same length
Each model's probabilities rank a memo's sentences. We took as many of its top sentences as the whole sections held, so the three are compared at the same length. Found is the share of marked sentences among those chosen; on target is the share of chosen sentences that were marked.
| Column | Sentences a memo | Whole sections | jev | SubQ |
|---|---|---|---|---|
| Mechanism of action | 18.9 | 41% found · 28% on target | 51% found · 49% on target | 57% found · 52% on target |
| Route of administration | 10.8 | 28% found · 8% on target | 57% found · 20% on target | 57% found · 22% on target |
| Primary endpoint | 33.5 | 0% found · 0% on target | 90% found · 8% on target | 83% found · 7% on target |
| Partner or licensing deal | 4.2 | 22% found · 28% on target | 28% found · 32% on target | 25% found · 28% on target |
| Patent expiry | 14.2 | 100% found · 24% on target | 100% found · 24% on target | 100% found · 24% on target |
- Mechanism of action is where sentence-by-sentence judging helps most. The topic is spread across the memo, and the sections found 41% of it.
- Primary endpoint is where jev's lead is largest. The sections found none of it: for this column they picked the memo's list of trial registrations instead.
- Patent expiry sits in one section, on intellectual property, so the sections found all of it and so did both models.
When each model chooses its own length
A filled cell should not need a fixed number of sentences. So we also kept every sentence each model gave better-than-even odds. On mechanism of action, SubQ kept 30.3 sentences a memo and found 95% of the marked ones; jev kept 27.9 and found 78%.
| Column | jev: kept a memo · found · on target | SubQ: kept a memo · found · on target |
|---|---|---|
| Mechanism of action | 27.9 · 78% · 54% | 30.3 · 95% · 55% |
| Route of administration | 11 · 65% · 29% | 12.8 · 70% · 26% |
| Primary endpoint | 6.7 · 70% · 30% | 13.3 · 70% · 15% |
| Partner or licensing deal | 7.3 · 72% · 34% | 6 · 80% · 47% |
| Patent expiry | 3.3 · 86% · 80% | 3.5 · 90% · 81% |
On patent expiry both keep about three sentences a memo and are right about 81% of the time. On primary endpoint jev is the more careful of the two: it keeps half as many sentences, and twice as many of them are marked.
How often they agree, and what it cost
We also put 6,296 questions to both on columns no one marked (indication, development stage, efficacy results, safety, dosing and others) on three more memos. They gave the same answer to 98% of them, mostly the easy no's. Of the sentences either one said yes to, they both did on 253 of 383.
jev read 2,263,852 tokens of input for the scored run, and its responses reported a cost of $0.10. SubQ read 1,697,123; at its preview price of $0.05 a million input tokens that is $0.08. A token is a piece of a word; the two count them differently, which is why the same questions came to different totals.
What can still go wrong
- This is a small test. Ten memos, five columns, one person's marks and one run of each model. A gap of a few points on 6 memos is a hint, not a ranking.
- Only exact sentences count. A model that chose a different sentence saying the same thing got no credit for it.
- Finding is not filling. This measures the first step. Turning the sentences found into a short cell, and checking it belongs to the right drug, is still to come.
- SubQ is in preview. Its price and its model may change.
- Run on 13 October 2026. SubQ is subq-snap-preview on SubQ's Decisions API; jev is typesafe/jev-1.13, reached through hedwigai's portal.
- Each question showed the model the sentence, the one before and after it, and the heading it sat under, and asked about the sentence alone. The two got the same 8,357 questions, word for word, grouped by sentence: up to 16 in a request for SubQ, all of a sentence's columns at once for jev.
- Whole sections are hedwigai's section search, asked for each column in plain words.
- jev's cost is what its responses reported for the scored run; SubQ's is its published preview price times the tokens it reported. Neither is what an account is charged.
More head-to-head evals
| Measure | ask | Apollo | treg |
|---|---|---|---|
| Usable leads | 13 of 40 | 7 of 40 | 6 of 28 |
| Cost per usable lead | $0.037 | $0.27 | $0.23 |
| Measure | ask with jev | ask with Decider |
|---|---|---|
| Questions right, of 92 | 89 | 89 |
| Wrong answers | 1 | 2 |
| Measure | jev | ask |
|---|---|---|
| Our 370 clinical decisions, right | 94.6% | 93.0% |
| PubMedQA, right (best EdgeEvals scored: 62.2%) | 77.0% | 74.4% |
| Measure | ask | Claude Opus 5.5 |
|---|---|---|
| Questions right, of 95 | 59 | 63 |
| Small companies right, of 20 | 13 | 9 |
| Measure | realestate-us | Best of four assistants |
|---|---|---|
| Floor-plan rents right, of 26 | 26 | 23 |
| Amenities claimed the listing doesn't state | 12 | 129 |
| Measure | ask | jev |
|---|---|---|
| Right, of the questions answered | 98% | 79% |
| Wrong answers, of 92 | 2 | 19 |
| Measure | Trained localiser | Best of four frontier models |
|---|---|---|
| Mean overlap with the defect (IoU, 0 to 1) | 0.421 | 0.109 |